Clinical trials · Philadelphia, PA
Esophageal Adenocarcinoma clinical trials in Philadelphia
We’re tracking 13 recruiting esophageal adenocarcinoma studies with a site in or near Philadelphia — including Phase 1, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Philadelphia
- NCT07431281RecruitingPhase 3
New drug combo for advanced stomach cancer with CLDN18.2
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06203600RecruitingPhase 2/Phase 3
Nivolumab plus standard treatment for advanced stomach or esophageal cancer
This trial tests whether adding the immunotherapy drug nivolumab to standard treatment works better for advanced stomach or esophageal cancer. It is for people whose cancer has already progressed after a first round of chemo plus immunotherapy.
Philadelphia, PennsylvaniaAges 18 years+ - NCT00288119Recruiting
Study genes in Barrett’s esophagus and esophageal cancer
This study looks at genetic (inherited) factors that may be linked to Barrett’s esophagus and esophageal cancer. It may help researchers understand why these conditions happen in some families and others do not.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07124000Recruiting
T-DXd for advanced HER2-positive solid tumors
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
Philadelphia, PennsylvaniaAges 18–130 - NCT06340711RecruitingPhase 2
Gene therapy plus Keytruda for advanced stomach or esophageal cancer
This study tests a new type of gene therapy (OBP-301) injected directly into the tumor, combined with the immunotherapy drug Keytruda (pembrolizumab), for people with advanced stomach, junction, or esophageal cancer. Researchers want to see if this combination can help when standard treatments have stopped working.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05753748Recruiting
Compare watchful waiting vs endoscopy treatment for Barrett’s with low-grade dysplasia
This trial compares two approaches for people with Barrett’s esophagus and low-grade dysplasia: regular monitoring versus treatment done through an endoscopy. It aims to see which approach is safer and better at preventing progression to more serious changes in the esophagus.
Philadelphia, PennsylvaniaAges 18–89 - NCT05677490RecruitingPhase 3
Chemo options, with or without nivolumab, for HER2-negative stomach cancer
This Phase 3 trial compares two standard chemotherapy regimens for advanced stomach, esophagus, or gastroesophageal junction cancer that is HER2-negative. It also tests whether adding nivolumab (an immune therapy) improves outcomes.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07182149RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called NRM-823 for people with several types of advanced cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06123338RecruitingPhase 2
Pembrolizumab plus chemo and trastuzumab for HER2+ stomach cancer
This trial tests adding pembrolizumab to standard trastuzumab and chemotherapy for people with HER2-positive stomach or esophageal cancer that can be fully removed with surgery. The goal is to see if this combination improves outcomes before and after surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05059444Recruiting
Blood test study to watch for cancer coming back
This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07392892RecruitingPhase 2/Phase 3
Study of PF-08634404 plus chemo for stomach and esophagus cancer
This trial tests a new study drug called PF-08634404 in combination with standard chemotherapy for people with stomach, gastroesophageal junction, or esophagus cancer that has spread. It aims to see if adding this drug helps the treatment work better.
Wynnewood, PennsylvaniaAges 18 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Mullica Hill, New JerseyAges 40–75 - NCT05799274RecruitingPhase 1
Safety study of a new PET imaging drug for cancers
This Phase 1 study tests how safe RAD301 is and how it behaves in the body when given for PET imaging in healthy volunteers and people with certain cancers. It may help doctors learn whether this imaging drug can clearly show cancer areas and be tolerated well.
Princeton, New JerseyAges 18 years+
Hear when a new Esophageal Adenocarcinoma trial opens near Philadelphia, PA
We’ll email you when one opens near Philadelphia, PA — at most once a week, no account needed, unsubscribe anytime.
Esophageal Adenocarcinoma trials in other cities
Where these studies are running near Philadelphia
Institutions with a site for the recruiting esophageal adenocarcinoma studies listed above.
- University of Pennsylvania · 5 studies
- Lehigh Valley Hospital - Muhlenberg · 3 studies
- Lehigh Valley Hospital-Cedar Crest · 3 studies
- Asplundh Cancer Pavilion · 2 studies
- Helen F Graham Cancer Center · 2 studies
- Jefferson Cherry Hill Hospital · 2 studies
- Medical Oncology Hematology Consultants PA · 2 studies
- Reading Hospital · 2 studies
What taking part in a esophageal adenocarcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting esophageal adenocarcinoma studies in Pennsylvania.
Common questions
- Are there esophageal adenocarcinoma clinical trials near Philadelphia?
- Yes. We're currently tracking 13 recruiting esophageal adenocarcinoma studies with a site near Philadelphia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a esophageal adenocarcinoma study near Philadelphia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Philadelphia to take part?
- Not necessarily. These studies have a site near Philadelphia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a esophageal adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New esophageal adenocarcinoma studies open near Philadelphia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.